AstraZeneca Reports Five-Year OlympiAD Data for Lynparza in BRCA-Mutated Breast Cancer

AstraZeneca today presented five-year overall survival data from the Phase 3 OlympiAD trial evaluating Lynparza (olaparib) versus chemotherapy in patients with HER2-negative metastatic breast cancer and germline BRCA mutations. The data showed a clinically meaningful improvement in overall survival with Lynparza, with a median overall survival of 22.6 months compared to 17.0 months in the chemotherapy arm.